J Korean Med Sci.  2024 Feb;39(6):e74. 10.3346/jkms.2024.39.e74.

Could Molnupiravir Be the First-Line Alternative Oral Antiviral Agent for COVID-19 Patients at High Risk?

• Lee JY

• KMID: 2553311
• DOI: http://doi.org/10.3346/jkms.2024.39.e74

Reference

1. U.S. Food and Drug Administration. Authorizations of Emergency Use of Certain Drugs and Biological Products During the COVID-19 Pandemic; Availability. Updated 2022. Accessed January 29, 2024. https://www.federalregister.gov/documents/2022/02/04/2022-02359/authorizations-of-emergency-use-of-certain-drugs-and-biological-products-during-the-covid-19 .

2. Mahase E. Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 2021; 375:n2713. PMID: 34750163.

3. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022; 386(6):509–520. PMID: 34914868.

4. National Institutes of Health. Molnupiravir. COVID-19 treatment guidelines. Updated 2023. Accessed January 30, 2024. https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/molnupiravir/?utm_source=site&utm_medium=home&utm_campaign=highlights .

5. Jang YR, Oh Y, Kim JY. Determining and comparing the real-world effectiveness of molnupiravir and nirmatrelvir-ritonavir in patients hospitalized with COVID-19. J Korean Med Sci. 2024; 39(6):e52.

6. Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022; 22(12):1681–1693. PMID: 36029795.

7. Wan EYF, Yan VKC, Mok AHY, Wang B, Xu W, Cheng FWT, et al. Effectiveness of molnupiravir and nirmatrelvir-ritonavir in hospitalized patients with COVID-19: a target trial emulation study. Ann Intern Med. 2023; 176(4):505–514. PMID: 36913693.

8. Kidd MR, Kelly PM. PANORAMIC: important insights into molnupiravir use in COVID-19. Lancet. 2023; 401(10373):250–251. PMID: 36566762.

9. Park JJ, Kim H, Kim YK, Lee SS, Jung E, Lee JS, et al. Effectiveness and adverse events of Nirmatrelvir/Ritonavir versus molnupiravir for COVID-19 in outpatient setting: multicenter prospective observational study. J Korean Med Sci. 2023; 38(42):e347. PMID: 37904658.

10. Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023; 401(10373):281–293. PMID: 36566761.